Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro.

Autor: Gilham D; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Smith AL; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 986805 NE Med Center, BCC 4.12.396, Omaha, NE 68198, USA., Fu L; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Moore DY; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 986805 NE Med Center, BCC 4.12.396, Omaha, NE 68198, USA., Muralidharan A; Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198, USA., Reid SPM; Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198, USA., Stotz SC; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Johansson JO; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Sweeney M; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Wong NCW; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Kulikowski E; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., El-Gamal D; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 986805 NE Med Center, BCC 4.12.396, Omaha, NE 68198, USA.
Jazyk: angličtina
Zdroj: Biomedicines [Biomedicines] 2021 Apr 18; Vol. 9 (4). Date of Electronic Publication: 2021 Apr 18.
DOI: 10.3390/biomedicines9040437
Abstrakt: Effective therapeutics are urgently needed to counter infection and improve outcomes for patients suffering from COVID-19 and to combat this pandemic. Manipulation of epigenetic machinery to influence viral infectivity of host cells is a relatively unexplored area. The bromodomain and extraterminal (BET) family of epigenetic readers have been reported to modulate SARS-CoV-2 infection. Herein, we demonstrate apabetalone, the most clinical advanced BET inhibitor, downregulates expression of cell surface receptors involved in SARS-CoV-2 entry, including angiotensin-converting enzyme 2 (ACE2) and dipeptidyl-peptidase 4 (DPP4 or CD26) in SARS-CoV-2 permissive cells. Moreover, we show that apabetalone inhibits SARS-CoV-2 infection in vitro to levels comparable to those of antiviral agents. Taken together, our study supports further evaluation of apabetalone to treat COVID-19, either alone or in combination with emerging therapeutics.
Databáze: MEDLINE
Externí odkaz: